Form 8-K - Current report:
SEC Accession No. 0001193125-24-217302
Filing Date
2024-09-11
Accepted
2024-09-11 16:57:01
Documents
15
Period of Report
2024-09-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d869021d8k.htm   iXBRL 8-K 30364
2 EX-10.1 d869021dex101.htm EX-10.1 85431
6 GRAPHIC g869021dsp1.jpg GRAPHIC 6090
  Complete submission text file 0001193125-24-217302.txt   273322

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ovid-20240908.xsd EX-101.SCH 2848
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ovid-20240908_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ovid-20240908_pre.xml EX-101.PRE 11260
17 EXTRACTED XBRL INSTANCE DOCUMENT d869021d8k_htm.xml XML 3633
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

EIN.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 241293170
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)